SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board: 
Last Post: 11/24/2017 5:02:05 AM - Followers: 195 - Board type: Free - Posts Today: 1

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

SureTrader
Interactive Brokers Advertisement
CVM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM News: Current Report Filing (8-k) 11/22/2017 05:18:54 PM
CVM News: CEL-SCI Announces Update on Arbitration against Former Clinical Research Organization 11/13/2017 07:30:00 AM
CVM News: Statement of Changes in Beneficial Ownership (4) 11/06/2017 01:06:28 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 11/06/2017 12:50:16 PM
CVM News: Current Report Filing (8-k) 11/03/2017 05:20:53 PM
PostSubject
#12120  Sticky Note CEL-SCI Granted European Patent for Multikine’s Mechanism of trickledownfacists 10/10/17 08:40:02 AM
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#12259   Could be the restatement linked to the arbitration? lux1 11/24/17 05:02:05 AM
#12258   Of course you could be correct in your warfaretrader 11/23/17 09:50:05 AM
#12257   Btw; I’m waiting for restatement of financials based learning curve 11/23/17 05:02:04 AM
#12256   I couldn’t spell facetious correctly without auto correct... learning curve 11/23/17 04:54:58 AM
#12255   authenticity is a good reason. Your failure to learning curve 11/23/17 04:08:20 AM
#12254   Non-Reliance on Previously Issued Financial Statements or a trickledownfacists 11/22/17 05:49:02 PM
#12253   If CLSN can move like that we can too Mtzzz 11/22/17 12:08:01 PM
#12252   I was being facetious is case you didn't warfaretrader 11/22/17 10:36:02 AM
#12251   No need to fill a page with complete posts Foxwoods Man 11/22/17 06:29:42 AM
#12250   If arbitration will be won or if ,more lux1 11/22/17 06:03:52 AM
#12249   Keep wishing.... learning curve 11/22/17 01:59:55 AM
#12248   Yeah well, "unless they agree to other terms" lightrock 11/22/17 01:59:38 AM
#12247   Who said those quotes? In that context that learning curve 11/22/17 01:55:57 AM
#12246   https://www.finra.org/arbitration-and-mediation/decision-award 30 days is the t sinity 11/22/17 01:51:34 AM
#12245   Exactly. I just don't want expectations to lightrock 11/22/17 12:00:53 AM
#12244   Whatever it is let's just get it over trickledownfacists 11/21/17 08:41:27 PM
#12243   Keep in mind - even if there is lightrock 11/21/17 04:54:57 PM
#12242   CEL-SCI Announces Update on Arbitration against Former Clinical mick 11/21/17 12:49:35 PM
#12241   Statement of Changes in Beneficial Ownership (4) "Edgar mick 11/21/17 12:49:29 PM
#12240   how thought provoking Trustbaby 11/21/17 12:41:58 PM
#12239   Cel-Sci Corp. ($0.0 (CVM) mick 11/21/17 12:27:44 PM
#12238   I hope not. Sure would be nice to Trustbaby 11/21/17 10:54:47 AM
#12237   You think it's coming? trickledownfacists 11/21/17 10:46:31 AM
#12236   What kind of Grinch would wait until Thanksgiving Trustbaby 11/21/17 10:40:42 AM
#12235   Gosh I wish I could be as smart warfaretrader 11/21/17 08:53:36 AM
#12234   11/16 I sold my small holding stake Foxwoods Man 11/21/17 07:13:01 AM
#12233   The transaction must cross the exchange...as it did learning curve 11/21/17 02:33:15 AM
#12232   It’s obvious you have no clue or interest learning curve 11/21/17 02:30:43 AM
#12231   the good is that another company is confident lux1 11/20/17 03:56:01 PM
#12230   Pretty typical from every volume move we've every warfaretrader 11/20/17 02:57:45 PM
#12229   Interesting trickledownfacists 11/20/17 01:54:07 PM
#12228   Broke trickledownfacists 11/20/17 01:21:20 PM
#12227   Volume! If this breaks through $2.00 could warfaretrader 11/20/17 01:16:30 PM
#12226   Volume just picks up immensely! trickledownfacists 11/20/17 01:14:46 PM
#12225   Thanks for posting about IRX. Spideyboy 11/20/17 09:09:38 AM
#12224   I'm surprised how IRX Therapeutics ( a private lux1 11/19/17 04:16:24 PM
#12223   Theyre going to win in arbitration big Mtzzz 11/19/17 02:27:57 PM
#12222   I wish you the best in your short warfaretrader 11/18/17 07:36:44 PM
#12221   That is why it is right for CVM lux1 11/18/17 09:10:18 AM
#12220   they cannot disclose the numbers. In principle only lux1 11/17/17 05:08:22 PM
#12219   Geert has always said that there would be Foxwoods Man 11/17/17 11:58:34 AM
#12218   In continuation of my just prior post on Spideyboy 11/17/17 11:28:25 AM
#12217   Ok so I'm still confused as to how Spideyboy 11/17/17 10:32:39 AM
#12216   Ahhh..that explains the rise in the last week Foxwoods Man 11/17/17 07:03:17 AM
#12215   could CVM disclose something like an interim result? lux1 11/17/17 04:58:01 AM
#12214   K. You stick to pretty sure. learning curve 11/16/17 11:27:16 PM
#12213   I had the same (but less well constructed) Foxwoods Man 11/16/17 07:24:31 AM
#12212   Like it akamaii 11/15/17 08:34:25 PM
#12211   This is my understanding of the point Spideyboy: drkazmd65 11/15/17 05:42:53 PM
#12210   ok so I looked into this 3 year Spideyboy 11/15/17 05:33:38 PM
PostSubject